Myriad Genetics, Inc.(NASDAQ : MYGN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.35%||64.70||1.0%||$546.77m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.42%||273.47||1.9%||$494.63m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.25%||691.95||2.6%||$439.95m|
|SNSS||Sunesis Pharmaceuticals, Inc.||1.91%||2.14||0.7%||$149.59m|
|EXAS||EXACT Sciences Corp.||7.50%||53.60||17.7%||$137.81m|
|TXG||10X Genomics, Inc.||11.30%||52.70||0.0%||$105.86m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.50%||80.83||4.2%||$96.91m|
|CRSP||CRISPR Therapeutics AG||5.09%||58.04||0.6%||$84.49m|
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.